Home Investing AstraZeneca revenues up as it delivers jab to 120 countries via Covax

AstraZeneca revenues up as it delivers jab to 120 countries via Covax




AstraZeneca has generated $275m (£197m) in revenues from its Covid vaccine in the first three months of the year and shipped 48m doses to 120 countries through the global vaccine-sharing initiative Covax.

Most of the vaccine sales ($224m) were in Europe – as the Anglo-Swedish drugmaker reported overall quarterly revenues up 15% to $7.3bn, better than analysts had expected. New medicines, such as the diabetes drug Farxiga, contributed more than half of revenues. The firm made a pre-tax profit of $1.6bn, up 72% year-on-year.

US rivals Pfizer and Moderna expect to make billions of dollars from their coronavirus vaccines, but AstraZeneca has pledged to make its jab available on a not-for-profit basis during the current pandemic. It made a loss of 3 cents a share on the vaccine in the first quarter.

AstraZeneca’s vaccine is seen as a lifeline for poorer countries, as it is cheaper and easier to store and transport than some of the other coronavirus vaccines being produced. The company said 80% of the Covax shipments went to low and middle-income countries. In total, it has so far supplied more than 300m vaccine doses to more than 165 countries.

[Read More…]

Linda Barbara

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum imperdiet massa at dignissim gravida. Vivamus vestibulum odio eget eros accumsan, ut dignissim sapien gravida. Vivamus eu sem vitae dui.

Recent posts